Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins

Drugs

Volumn 59, Issue SUPPL. 3, 2000, Pages 29-35

  Tice, Alan D ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Infectious Ltd   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN; NAFCILLIN; PIPERACILLIN; TICARCILLIN; VANCOMYCIN;

AMBULATORY CARE; BACTEREMIA; CELLULITIS; COST MINIMIZATION ANALYSIS; CYSTIC FIBROSIS; ECONOMIC EVALUATION; ENDOCARDITIS; HEALTH CARE COST; HOSPITAL; HOSPITAL CARE; HUMAN; INFECTION; MANAGED CARE; OSTEOMYELITIS; OUTPATIENT CARE; PATIENT; PHYSICIAN; REVIEW; SOFT TISSUE INFECTION; WOUND INFECTION;

EID: 0033949385     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059003-00004     Document Type: Review

References (37)

1. Rucker RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54 (3): 358-60
2. Winters RW. The home infusion therapy industry: an overview. In: Conners RB, Winters RW, editors. Current status and future trends. American Hospital Publishing, Inc. 1995: 1-15
3. Milkovich G. Costs and benefits. Hosp Pract Off Ed 1993; 28 Suppl. 1: 39-43
4. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. Am J Med 1989; 87: 301-5
5. Antoniskis A, Anderson BC, Van-Volkinburg EJ, et al. Feasibility of outpatient self-administration of parenteral antibiotics. West J Med 1978; 128: 203-6
6. Poretz DM, Eron LJ, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248: 336-9
7. Rehm SJ, Weinstein AJ. Home intravenous antibiotic therapy: a team approach. Ann Intern Med 1983; 99: 388-92
8. Eron LJ. Intravenous antibiotic administration in outpatient settings. Infect Dis 1982; 14: 4-11
9. Poretz DM, Woolard D, Eron LJ, et al. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77: 77-83
10. Kind AC, Williams DN, Gibson J. Outpatient intravenous antibiotic therapy. Ten years' experience. Postgrad Med 1985; 77: 105-8, 111
11. Manzella JP, McConville JH, Klaus B, et al. Home intravenous antibiotic therapy. Pa Med 1985; 33: 52-4
12. Graves G, Jackson JP, Maxwell A, et al. Home intravenous antibiotic therapy in Arkansas. J Ark Med Soc 1987; 84: 55-7
13. Harris LF, Buckle TF, Coffey FL. Intravenous antibiotics at home. South Med J 1986; 79: 193-6
14. Kane RE, Jennison K, Wood C, et al. Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol 1988; 4: 84-9
15. Williams DN, Bosch D, Boots J, et al. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. Clin Ther 1993; 15 (1): 169-79
16. Tree AD. Patient selection criteria for outpatient parenteral antibiotic therapy - experience with a physician directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 23-9
17. Hindes R, Winkler C, Kane P, et al. Outpatient intravenous antibiotic therapy in medicare patients: cost-savings analysis. Infect Dis Clin Pract 1995; 4: 211-7
18. Alternate site care - infusion industry update. Investment advisory report. Boston, MA: Cowan & Co., 1993
19. Eckman MH, Steere AC, Kalish RA, et al. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early lyme disease or lyme arthritis. N Engl J Med 1997; 337: 357-63
20. Fine MJ, Singer DE, Marrie TJ, et al. Medical outcomes of ambulatory and hospitalised low risk patients with community-acquired pneumonia [abstract]. J Gen Intern Med 1994 Apr; 9 Suppl.: 29A
21. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996; 17: 552-7
22. van Adrichem JAM. Insurance companies' view on outpatient treatment. Int J Antimicrob Agents 1995; 5: 35-8
23. Tice AD. Outpatient parenteral antibiotic therapy in different countries. Int J Infect Dis 1996; 1: 102-6
24. Tice AD. Alternate site infusion: the physician-directed, office-based model. J Intraven Nurs 1996; 19: 188-93
25. Tice AD. The importance of teamwork for outpatient parenteral antibiotic therapy. Int J Antimicrob Agents 1995; 5: 13-7
26. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 4-10
27. Graninger W, Wenisch C, Wiesenger E, et al. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 11-5
28. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995; 39: 1247-52
29. Schleis TG, Tice AD. Selecting infusion devices for use in ambulatory care. Am J Health Syst Pharm 1996; 53: 868-77
30. Grizzard MB, Harris G, Karns H. Use of outpatient parenteral antibiotic therapy in a health maintenance organization. Rev Infect Dis 1991; 13 Suppl. 2: S174-9
31. Hitt CM, Nightingale CH, Quintiliani R, et al. Cost comparison of single daily IV doses of ceftriaxone versus continuous infusion of cefotaxime. Am J Health-Syst Pharm 1997; 54: 1614-8
32. Tice AD, Slama TG, Berman S, et al. Managed care and the infectious diseases specialist. Clin Infect Dis 1996; 23: 341-68
33. Pond MN, Newport M, Joanes D, et al. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. Eur Respir J 1994; 7: 1640-4
34. Caplan GA, Ward JA, Brennan NJ, et al. Hospital in the home: a randomised controlled trial. Med J Aust 1999; 170 (4): 156-60
35. Wickline v. State of California. 239 Cal Rptr. (Cal. App. 2 Dist, 1986): 810-20
36. Kunkel MJ. Quality assurance. Hosp Pract Off Ed 1993; 28 Suppl. 1:33-8
37. Goodpasture H. What's new in Wichita. OPIVITA Newsletter 1993; (4) 7-8: Tacoma, WA: OPIVITA